T-cell lymphomas

T-cell lymphomas: therapeutic possibilities for a limited choice

MY CHOISE , , , , ,

V.A. Doronin

N.N. Blokhin Russian Cancer Research Center, RAMS, Moscow, Russian Federation

ABSTRACT

Peripheral and cutaneous T-cell lymphomas (PTCLs and CTCLs) are a group of distinct non-Hodgkin’s lymphomas (NHLs) with wide variation of molecular and genetic features, symptom patterns, and clinical manifestations. The diversity and rarity of these hematological disorders make clinical studies difficult, and treatment is improving slower than in more common B-cell NHLs. Thus, no standard therapies have been established for T-cell lymphomas so far. Treatment is often conducted within the frame of clinical trials. This article offers perspectives regarding the tailoring of treatment for patients with PTCL and CTCL. Novel therapies are also discussed.

Keywords: T-cell lymphomas, peripheral T-cell lymphoma, not otherwise specified, angioimmunoblastic T-cell lymphoma, anaplastic large cell lymphoma, cutaneous T-cell lymphomas.

Read in  PDF (RUS)pdficon

REFERENCES

  1. World Health Organization. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. Lyon: IARC Press, 2008.
  2. Vose J., Armitage J., Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J. Clin. Oncol. 2008; 26(25): 4124–30.
  3. Petrich A.M., Helenowski I., Galamaga R.W., Nabhan C. Blood (ASH Annual Meeting Abstracts) 2012; 120: Abstract 4264.
  4. Savage K.J., Chhanabhai M., Gascoyne R.D. et al. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann. Oncol. 2004; 15: 1467–75.
  5. Schmitz N., Trumper L., Ziepert M. et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 2010; 116: 3418–25.
  6. Gallamini A., Zaja F., Patti C. et al. Alemtuzumab (Campath-1H) and CHOP сhemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 2007; 110: 2316–23.
  7. Mahadevan D., Unger J.M., Persky D.O. et al. Phase II trial of cisplatin plus etoposide plus gemcitagine plus solumedrol (PEGS) in peripheral T-cell non-Hodgkin lymphoma (SWOG S0350). Ann. Oncol. 2011; 22.
  8. Rodriguez J., Conde E., Gutierrez A. et al. Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group. Eur. J. Haematol. 2007; 79: 32–8.
  9. Mercadal S. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann. Oncol. 2008; 19: 958–63.
  10. Reimer P., Rudiger T., Geissinger E. et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J. Clin. Oncol. 2009; 27: 106–13.
  11. d’Amore F., Relander T., Lauritzsen G.F. et al. High-dose chemotherapy and autologuos stem cell transplantation in previously untreated peripheral T-cell lymphoma — final analysis of a large prospective multicenter study (NLGT-01). J. Clin. Oncol. 2012; 30(25): 3093–9.
  12. Farcet J.P., Gaulard P., Marolleau J.P. et al. Hepatosplenic T-cell lymphoma: sinusal/sinusoidal localization of malignant cells expressing the T-cell receptor gamma delta. Blood 1990; 75(11): 2213–9.
  13. Schmidt L.A., Lim M.S. T cell lymphoproliferative disorders associated with anti-tumor necrosis factor alpha antibody therapy for ulcerative colitis: literature summary. J. Hematop. 2009; 2(2): 121–6.
  14. Kotlyar D.S., Osterman M.T., Diamond R.H. et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 2011; 9(1): 36–41.
  15. Miyazaki K., Yamaguchi M., Imai H. et al. Gene expression profiling of peripheral T-cell lymphoma including gamma/delta T-cell lymphoma. Blood 2009; 113(5): 1071–4.
  16. Falchook G.S., Vega F., Dang N.H. et al. Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment. Ann. Oncol. 2009; 20(6): 1080–5.
  17. Willemze R., Jansen P.M., Cerroni L. et al. Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood 2008; 111(2): 838–45.
  18. Go R.S., Wester S.M. Immunophenotypic and molecular features, clinical outcomes, treatments, and prognostic factors associated with subcutaneous panniculitis-like T-cell lymphoma: a systematic analysis of 156 patients reported in the literature. Cancer 2004; 101(6): 1404–13.
  19. Salhany K.E., Macon W.R., Choi J.K. et al. Subcutaneous panniculitis-like T-cell lymphoma: clinicopathologic, immunophenotypic, and genotypic analysis of alpha/beta and gamma/delta subtypes. Am. J. Surg. Pathol. 1998; 22(7): 881–93.
  20. Jantunen E., Boumendil A., Finel H. et al. Autologous Stem Cell Transplantation (ASCT) for Enteropathy-Associated T-Cell Lymphoma (EATL): Final Analysis of a Retrospective Study On the Behalf of Lymphoma Working Party (LWP) of the European Group for Blood and Marrow Transplantation (EBMT). Blood (ASH Annual Meeting Abstracts) 2012; 120: Abstract 3105.
  21. Kim G.E., Cho J.H., Yang W.I. et al. Angiocentric lymphoma of the head and neck: patterns of systemic failure after radiation treatment. J. Clin. Oncol. 2000; 18(1): 54–63.
  22. Li Y.X., Yao B., Jin J. et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J. Clin. Oncol. 2006; 24(1): 181–9.
  23. Kim W.S., Song S.Y., Ahn Y.C. et al. CHOP followed by involved field radiation: is it optimal for localized nasal natural killer/T-cell lymphoma? Ann. Oncol. 2001; 12(3): 349–52.
  24. Yamaguchi M., Kwong Y.L., Kim W.S. et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J. Clin. Oncol. 2011; 29(33): 4410–6.
  25. Willemze R., Kerl H., Sterry W. et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 1997; 90: 354–71.
  26. Willemze R., Jaffe E.S., Burg G. et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768–85.
  27. Macaulay W.L. Lymphomatoid papulosis. A continuing self-healing eruption, clinically benign–histologically malignant. Arch. Dermatol. 1968; 97(1): 23–30.
  28. Bekkenk M.W., Geelen F.A., van Voorst Vader P.C. et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 2000; 95: 3653–61.
  29. Liu H.L., Hoppe R.T., S. Kohler et al. CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. J. Am. Acad. Dermatol. 2003; 49(6): 1049–58.
  30. Bijl J.J., Rieger E., van Oostveen J.W. et al. HOXC4, HOXC5, and HOXC6 expression in primary cutaneous lymphoid lesions. High expression of HOXC5 in anaplastic large-cell lymphomas. Am. J. Pathol. 1997; 151: 1067–74.
  31. Vonderheid E.C., Sajjadian A., Kadin M.E. Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders. J. Am. Acad. Dermatol. 1996; 34(3): 470–81.
  32. Willemze R., Beljaards R.C. Spectrum of primary cutaneous CD30 (Ki-1)- positive lymphoproliferative disorders. A proposal for classification and guidelines for management and treatment. J. Am. Acad. Dermatol. 1993; 28(6): 973–80.
  33. Paulli M., Berti E., Rosso R. et al. CD30/Ki-1-positive lymphoproliferative disorders of the skin–clinicopathologic correlation and statistical analysis of 86 cases: a multicentric study from the European Organization for Research and Treatment of Cancer Cutaneous Lymphoma Project Group. J. Clin. Oncol. 1995; 13(6): 1343–54.
  34. Rijlaarsdam J.U., Huijgens P.C., Beljaards R.C. et al. Oral etoposide in the treatment of cutaneous large-cell lymphomas. A preliminary report of four cases. Br. J. Dermatol. 1992; 127(5): 524–8.
  35. Kim Y.H., Liu H.L., Mraz-Gernhard S. et al. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch. Dermatol. 2003; 139(7): 857–66.
  36. Ralfkiaer E. Controversies and discussion on early diagnosis of cutaneous T-cell lymphoma. Phenotyping. Dermatol. Clin. 1994; 12: 329–34.
  37. Vonderheid E.C., Bernengo M.G., Burg G. et al. Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J. Am. Acad. Dermatol. 2002; 46: 95–106.
  38. Agar N.S., Wedgeworth E., Crichton S. et al. Survival outcomes and prognostic factors in mycosis fungoides/Sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J. Clin. Oncol. 2010; 28(31): 4730–9.
  39. Olsen E.A., Rook A.H., Zic J. et al. Sezary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). J. Am. Acad. Dermatol. 2011; 64(2): 352–404.
  40. Kelly W.K., O’Connor O.A., Krug L.M. et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J. Clin. Oncol. 2005; 23(17): 3923–31.
  41. Kelly W.K., Richon V.M., O’Connor O. et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin. Cancer Res. 2003; 9(10 Pt. 1): 3578–88.
  42. O’Connor O.A., Heaney M.L., Schwartz L. et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J. Clin. Oncol. 2006; 24(1): 166–73.
  43. Mann B.S., Johnson J.R., Cohen M.H. et al. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007; 12(10): 1247–52.
  44. Duvic M., Talpur R., Ni X. et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007; 109(1): 31–9.
  45. Olsen E.A., Kim Y.H., Kuzel T.M. et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J. Clin. Oncol. 2007; 25(21): 3109–15.
  46. O’Connor O.A., Pro B., Pinter-Brown L. et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J. Clin. Oncol. 2011; 29(9): 1182–9.
  47. Marchi E., Paoluzzi L., Scotto L. et al. Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies. Clin. Cancer Res. 2010; 16(14): 3648–58.
  48. Horwitz S.M., Vose J.M., Advani R. et al. Pralatrexate and Gemcitabine in Patients with Relapsed or Refractory Lymphoproliferative Malignancies: Phase 1 Results. ASH Annual Meeting Abstracts 2009; 114: 1674.
  49. Coiffier B., Pro B., Prince H.M. et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J. Clin. Oncol. 2012; 30(6): 631–6.
  50. Pro B., Advani R., Brice P. et al. Durable remissions with brentuximab vedotin (SGN-35): updated results of a phase II study in patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). J. Clin. Oncol. 2011; 29: Abstract 8032